@wcnddtn

wcnddtn has been a member of Linktree for 3 years and joined in July 2023. The social media accounts linked to from wcnddtn are: • Instagram • LinkedIn • X Besides social media accounts, wcnddtn has populated their site with: • Applied Drug Discovery & Development (AD3) Certificate • Novel compounds open new research avenues for Alzheimer’s disease therapeutics | Basic Sciences | Vanderbilt University • Staff Spotlight: Joshua Wilkinson | Lindsley Lab | Vanderbilt University • Staff Spotlight: Snehal Sant | Lindsley Lab | Vanderbilt University • "Warren Center for Neuroscience Drug Discovery" - Search Results - PubMed • Pipeline — WCNDD • Vanderbilt Kennedy Center announces 2025–26 Nicholas Hobbs Discovery Award recipients - Notables • Staff Spotlight: Louise Dow | Lindsley Lab | Vanderbilt University • Vanderbilt honors 2025 Master Innovators who drive breakthrough research and commercial impact | Vanderbilt University • Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 • Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 - BioSpace • Vanderbilt’s Ancora Partnership: A collaborative journey toward health care innovation | Vanderbilt University • Optimization of Selective and CNS Penetrant Alkyne-Based TREK Inhibitors: The Discovery and Characterization of ONO-9517601 (VU6022856) and ONO-7927846 (VU6024391) | Journal of Medicinal Chemistry • Staff Spotlight – John Terrell, Ph.D. | Lindsley Lab | Vanderbilt University • Staff Spotlight – Jacob Bouchard, Ph.D., Drug Discovery Scientist | Lindsley Lab | Vanderbilt University • Cryo-EM reveals an extrahelical allosteric binding site at the M5 mAChR - Nature Communications • Profiling the Impact of mGlu7/Elfn1 Protein Interactions on the Pharmacology of mGlu7 Allosteric Modulators - PubMed • Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 | Neumora Therapeutics, Inc. • Staff Spotlight – Srinivasan Krishnan, Drug Discovery Scientist • Discovery of a Novel sp3-Rich M1 Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping • New Warren Center TREK channel compounds reveal power of academic-industry partnerships in drug discovery • Vanderbilt has developed internal funding programs to facilitate faculty research. • Sign up • Discovery of ONO-TR-772 (VU6018042): A Highly Selective and CNS Penetrant TREK Inhibitor in Vivo Tool Compound • Staff Spotlight – Elizabeth Childress, Drug Discovery Scientist I • Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 • One undergraduate’s path to treating brain cancer • Giving Day 2025 • Getting bang for your buck • The Impact of Cannabis & Drug Abuse on Brain Development | Kristen Gilliland, Ph.D. • OutreachAndAdvocacy | "Just the Facts" • Meet the departments: Pharmacology: A research enterprise on a pillar of excellence • Upcoming events. — Speaking Through Me • Wellcome Trust Discovery Award advances international collaboration to combat opioid misuse and addiction • Can't put down your phone? 7 easy tips to stop scrolling and enjoy a digital detox. • Staff Spotlight – Research Assistant Professor, Aaron Bender • Celebrating recent appointments and promotions in the School of Medicine Basic Sciences • Warren Center for Neuroscience Drug Discovery researchers create new compound to potentially treat negative and positive symptoms of schizophrenia • Tennessee Bureau of Investigation and Vanderbilt researchers to collaborate on opioid crisis, cannabis education • "Just the Facts" game - YouTube • Discovery of VU6024578/BI02982816: An mGlu1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models • First successful clinical trial of VU319 brings Alzheimer’s treatment one step closer • Vanderbilt CTTC honors five pioneering faculty as newly inducted Master Innovators • Medicinal Chemistry Education: Emphasize Fundamentals and Skillfully Integrate Knowledge • Q&A: Designing a backup for a drug compound to improve memory loss in people with Alzheimer's disease • Home — Speaking Through Me • Classics in Chemical Neuroscience: Tianeptine • Speaking Through Me - Upcoming Events • Sign up for WCNDD Newsletter! • Recent Publications • Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate - PubMed • scholargps.com • WCNDD Newsletter Vol. 2 Issue 4 • WCNDD Newsletter Vol. 2 Issue 3 — WCNDD • WCNDD Newsletter Volume 2 Issue 2 — WCNDD • Giving Day 2024 • WCNDD Newsletter Vol. 1 Issue 6 — WCNDD • Warren Center for Neuroscience Drug Discovery added to Discovery Vanderbilt portfolio; philanthropic matching launched • DARE TO GROW | Vanderbilt Giving • WCNDD Newsletter Vol.1 Issue 5 • Vanderbilt documentary ‘Speaking Through Me’ spotlights youth brain education for mental health and substance use disorder prevention • WCNDD Newsletter Vol. 1 Issue 4 — WCNDD • Speaking Through Me - Film Screening Premiere Followed by Guest Panel • Warren Center for Neuroscience Drug Discovery | LinkedIn • WCNDD (@WCNDD_TN) / Twitter • WCNDD (@wcndd_tn) • Instagram photos and videos